Pain management in advanced cancer: physical activity as an outcome - accelerometer feasibility study.

Lord, S; Good, P; Mielke, GI

Pain management in advanced cancer: physical activity as an outcome - accelerometer feasibility study.

Lord, S Good, P

Mielke, GI

Permalink

Publisher:: BMJ PUBLISHING GROUP
Publication Type:: Journal Article
Citation:: BMJ Support Palliat Care, 2022, pp. spcare-2022-003940
Issue Date:: 2022-09-13

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (511.09 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Lord, S
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.contributor.author	Mielke, GI
dc.date.accessioned	2022-12-02T02:24:25Z
dc.date.available	2022-08-30
dc.date.available	2022-12-02T02:24:25Z
dc.date.issued	2022-09-13
dc.identifier.citation	BMJ Support Palliat Care, 2022, pp. spcare-2022-003940
dc.identifier.issn	2045-435X
dc.identifier.issn	2045-4368
dc.identifier.uri	http://hdl.handle.net/10453/164054
dc.description.abstract	OBJECTIVE: Cancer pain is a common distressing symptom. Numerical Pain Scales (NPS) assess pain but lack information about function and quality of life. This feasibility study assesses the use of triaxial accelerometers to measure function as an outcome measure in pain studies in advanced cancer. METHODS: Advanced cancer participants were recruited from two palliative care services, with an average pain score of ≥3 on NPS. ActiGraph wGT3X-BT Accelerometers were worn for 1 week on the wrist. Patients recorded daily pain scores, Edmonton Symptom Assessment Scale (ESAS) scores, and their daily opioid use. RESULTS: 24 participants were recruited. A total of 142 days of accelerometer data was collected (5.9 days/participant). The average daily step count was 5723.7. The average acceleration was 14.4 milligravity units/day. An average of 93 min/day total activity across all intensities was recorded. No correlation was seen between acceleration or average daily minutes in activity and total daily oral morphine equivalent, ESAS, 'average pain' score or 'worst pain' scores using spearman's correlation coefficients. Overall, participants were satisfied with the study. CONCLUSIONS: Accelerometers are a feasible method to measure activity as an outcome measure in advanced cancer. Further study is required to assess the impact of pain management strategies on function.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	BMJ PUBLISHING GROUP
dc.relation.ispartof	BMJ Support Palliat Care
dc.relation.isbasedon	10.1136/spcare-2022-003940
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1110 Nursing, 1117 Public Health and Health Services
dc.title	Pain management in advanced cancer: physical activity as an outcome - accelerometer feasibility study.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
dc.date.updated	2022-12-02T02:24:24Z
pubs.publication-status	Published online

Abstract:

OBJECTIVE: Cancer pain is a common distressing symptom. Numerical Pain Scales (NPS) assess pain but lack information about function and quality of life. This feasibility study assesses the use of triaxial accelerometers to measure function as an outcome measure in pain studies in advanced cancer. METHODS: Advanced cancer participants were recruited from two palliative care services, with an average pain score of ≥3 on NPS. ActiGraph wGT3X-BT Accelerometers were worn for 1 week on the wrist. Patients recorded daily pain scores, Edmonton Symptom Assessment Scale (ESAS) scores, and their daily opioid use. RESULTS: 24 participants were recruited. A total of 142 days of accelerometer data was collected (5.9 days/participant). The average daily step count was 5723.7. The average acceleration was 14.4 milligravity units/day. An average of 93 min/day total activity across all intensities was recorded. No correlation was seen between acceleration or average daily minutes in activity and total daily oral morphine equivalent, ESAS, 'average pain' score or 'worst pain' scores using spearman's correlation coefficients. Overall, participants were satisfied with the study. CONCLUSIONS: Accelerometers are a feasible method to measure activity as an outcome measure in advanced cancer. Further study is required to assess the impact of pain management strategies on function.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/164054